CMPX - Compass Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

48.88M

Cash

168.8M

Avg Qtr Burn

-10.98M

Short % of Float

3.29%

Insider Ownership

15.69%

Institutional Own.

64.97%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CTX-009 (DLL4 and VEGF-A bispecific antibody) Details Cancer, Biliary Tract Cancer	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX-009 (DLL4 and VEGF-A bispecific antibody) Details Cancer, Colorectal cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX-471 (CD137 + PD-1) Details Cancer, Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX-8371 (PD-1 x PD-L1) Details Cancer	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.